Kazuya Sato

Dr. Kazuya Sato

orcid
Assistant Professor, Division of Hematology, Department of M...

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 September 2006 in Blood
Verified
Journal Article
Open access
PDF file
Kazuya SatoKazuya Sato
Kazuya Sato
KOKatsutoshi Ozaki
Katsutoshi Ozaki
IOIekuni Oh
Iekuni Oh
AMAkiko Meguro
Akiko Meguro
KHKeiko Hatanaka
Keiko Hatanaka
KOKeiya Ozawa
Keiya Ozawa
The molecular mechanisms by which mesenchymal stem cells (MSCs) suppress T-cell proliferation are poorly understood, and whether a soluble factor plays a major role remains controversial. Here we demonstrate that the T-cell–receptor complex is not a target for the suppression, suggesting that downstream signals mediate the suppression. We found that Stat5 phosphorylation in T cells is suppressed in the presence of MSCs and that nitric oxide (NO) is involved in the suppression of Stat5 phosphorylation and T-cell proliferation. The induction of inducible NO synthase (NOS) was readily detected in MSCs but not T cells, and a specific inhibitor of NOS reversed the suppression of Stat5 phosphorylation and T-cell proliferation. This production of NO in the presence of MSCs was mediated by CD4 or CD8 T cells but not by CD19 B cells. Furthermore, inhibitors of prostaglandin synthase or NOS restored the proliferation of T cells, whereas an inhibitor of indoleamine 2,3-dioxygenase and a transforming growth factor–β–neutralizing antibody had no effect. Finally, MSCs from inducible NOS−/− mice had a reduced ability to suppress T-cell proliferation. Taken together, these results suggest that NO produced by MSCs is one of the major mediators of T-cell suppression by MSCs.

13 October 2008 in Oncogene
Verified
Journal Article
Open access
PDF file
KHK Hatano
K Hatano
JKJ Kikuchi
J Kikuchi
MTM Takatoku
M Takatoku
RSR Shimizu
R Shimizu
TWT Wada
T Wada
KOK Ozawa
K Ozawa
Multiple myeloma (MM) is incurable, mainly because of cell adhesion-mediated drug resistance (CAM-DR). In this study, we performed functional screening using short hairpin RNA (shRNA) to define the molecule(s) responsible for CAM-DR of MM. Using four bona fide myeloma cell lines (KHM-1B, KMS12-BM, RPMI8226 and U266) and primary myeloma cells, we identified CD29 (β1-integrin), CD44, CD49d (α4-integrin, a subunit of VLA-4), CD54 (intercellular adhesion molecule-1 (ICAM-1)), CD138 (syndecan-1) and CD184 (CXC chemokine receptor-4 (CXCR4)) as major adhesion molecules expressed on MM. shRNA-mediated knockdown of CD49d but not CD44, CD54, CD138 and CD184 significantly reversed CAM-DR of myeloma cells to bortezomib, vincristine, doxorubicin and dexamethasone. Experiments using blocking antibodies yielded almost identical results. Bortezomib was relatively resistant to CAM-DR because of its ability to specifically downregulate CD49d expression. This property was unique to bortezomib and was not observed in other anti-myeloma drugs. Pretreatment with bortezomib was able to ameliorate CAM-DR of myeloma cells to vincristine and dexamethasone. These results suggest that VLA-4 plays a critical role in CAM-DR of MM cells. The combination of bortezomib with conventional anti-myeloma drugs may be effective in overcoming CAM-DR of MM.

1 May 2008 in Journal of Autoimmunity
Verified
Journal Article
Closed access
KOKeiya Ozawa
Keiya Ozawa
Kazuya SatoKazuya Sato
Kazuya Sato
IOIekuni Oh
Iekuni Oh
KOKatsutoshi Ozaki
Katsutoshi Ozaki
RURyosuke Uchibori
Ryosuke Uchibori
AKAkihiro Kume
Akihiro Kume

27 December 2011 in Cancer
Verified
Journal Article
Open access
PDF file
HTHiroyuki Takahashi
Hiroyuki Takahashi
NTNaoto Tomita
Naoto Tomita
MYMasahiro Yokoyama
Masahiro Yokoyama
STSaburo Tsunoda
Saburo Tsunoda
TYTakahiro Yano
Takahiro Yano
YIYoshiaki Ishigatsubo
Yoshiaki Ishigatsubo
BACKGROUND: Extranodal involvement is considered a poor prognostic factor for patients with diffuse large B‐cell lymphoma (DLBCL); however, the prognostic impact of specific sites of involvement has not been fully elucidated.METHODS: The authors retrospectively analyzed 1221 patients treated uniformly with standard R‐CHOP therapy between 2003 and 2006. Patients with distinct forms of DLBCL such as intravascular lymphoma, primary effusion lymphoma, pyothorax‐associated lymphoma, primary central nervous system lymphoma, and intraocular lymphoma were also excluded. The authors evaluated 26 extranodal sites of involvement with respect to prognostic impact. The median age was 64 years (range, 15‐91 years).RESULTS: Univariate analysis revealed that patients with involvement of specific extranodal sites had significantly worse overall survival (OS) than did patients without such involvement; these sites included nasal cavity, paranasal sinus, lung, pleura, small intestine, peritoneum, liver, pancreas, stomach, spleen, adrenal gland, testis, bone, bone marrow, peripheral blood, skin, and subcutaneous tissue. Patients with Waldeyer ring involvement had significantly better OS. Multivariate analysis revealed that patients with the involvement of the pleura (P < .001), small intestine (P = .015), peritoneum (P = .002), adrenal gland (P < .001), testis (P = .005), bone marrow (P < .001), and peripheral blood (P = .002) had significantly worse OS, whereas those with Waldeyer ring involvement had significantly better OS (P = .038). Subgroup analysis with the nodal and/or Waldeyer patient group also showed prognostic impact of Waldeyer ring by multivariate analysis (relative risk, 0.3; P = .04).CONCLUSIONS: Extranodal involvement affects the prognosis of patients undergoing R‐CHOP therapy for DLBCL. Cancer 2012. © 2011 American Cancer Society.

1 July 2011 in Cytotherapy
Verified
Journal Article
Closed access
PDF file
RTRaine Tatara
Raine Tatara
KOKatsutoshi Ozaki
Katsutoshi Ozaki
YKYuji Kikuchi
Yuji Kikuchi
KHKeiko Hatanaka
Keiko Hatanaka
IOIekuni Oh
Iekuni Oh
KOKeiya Ozawa
Keiya Ozawa

1 January 2010 in Journal of Clinical and Experimental Hematopathology
Verified
Journal Article
Open access
PDF file
Kazuya SatoKazuya Sato
Kazuya Sato
KOKatsutoshi Ozaki
Katsutoshi Ozaki
MMMasaki Mori
Masaki Mori
KMKazuo Muroi
Kazuo Muroi
KOKeiya Ozawa
Keiya Ozawa
Mesenchymal stromal cells (MSCs) have unique characteristics such immune suppression by inhibiting T cell proliferation, tissue-repair ability and acceleration of hemopoietic stem cell engraftment. The cells are rare in bone marrow, but easily cultured under standard culture conditions. Soluble factors and cells are implicated in the MSC-mediated T cell suppression and numerous clinical trials using MSCs to prevent and treat graft-versus-host disease (GVHD) have been reported. MSCs are suggested to suppress acute GVHD without impairing graft-versus-leukemia effects and increasing systemic infections. In this review, we focus on basic aspects of MSC-mediated T cell suppression and clinical trials using MSCs for GVHD and related conditions.